ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION)

E.B. Pavlinova; A.G. Mingairova; T.I. Safonova; T.Yu. Korneyeva

ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION)

E.B. Pavlinova, A.G. Mingairova, T.I. Safonova, T.Yu. Korneyeva

Abstract

Complications from the part of the respiratory apparatus are the main reason for the lethality among patients, suffering from mucoviscidosis. The adequate mucolytic therapy is of great importance in the complex treatment of the chronic bronchopulmonary process. In 2004, in Omsk center of mucoviscidosis, the researchers started to regularly apply a new mucolytimedication dornase alfa in treatment of children (Pulmozyme, F. Hoffmann La Roche Ltd., Switzerland). The results of the two year observation showed that dornase alfa may successfully be used in complex therapy of patients, suffering from mucoviscidosis, as well as periodical and chronic colonization of the respiratory tracts by Pseudomonas aeruginosa.
Key words: mucoviscidosis, children, dornase alfa.

About the Authors

E.B. Pavlinova

State Medical Academy, Omsk
Russian Federation

A.G. Mingairova

State Medical Academy, Omsk
Russian Federation

T.I. Safonova

Regional Children's Clinical Hospital, Omsk
Russian Federation

T.Yu. Korneyeva

State Medical Academy, Omsk
Russian Federation

References

1. Капранов Н.И., Каширская Н.Ю. Муковисцидоз. Методические рекомендации. М. 2005. 104 с.

2. Quan J.M., Tiddens H.A., Sy J.P. et al. A two year randomized, placebo controlled trial of dornase alfa in young patients wish cystic fibrosis and mild lung function abnormalities. Journal of Pediatrics. 2001; 139: 813–820.

3. Капранов Н.И., Воронкова А.Ю. Клиническое значение ДНК в комплексной терапии больных муковисцидозом. Российский педиатрический журнал. 2001; 4: 26–31.

4. Воронкова А.Ю. Клинические эффекты применения Пульмозима. VII Национальный конгресс по муковисцидозу. Сб. статей и тезисов. М. 2005. 40 с.

5. Robinson P. Dornase alfa in early CF lung disease. Pediatric Pulmonology. 2002; 34: 237–241.

Review

For citations:

Pavlinova E., Mingairova A., Safonova T., Korneyeva T. ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION). Current Pediatrics. 2007;6(2):102-106.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me

User

Current Pediatrics

ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION)

Abstract

About the Authors

References

Review

For citations:

Cookies policy